CASIF on OTC
CASI Pharmaceuticals, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with SCYNEXIS INC, Evofem Biosciences, Inc. or Prenetics Global Ltd, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
48.6%Gross margin2
-217.3%Operating margin2
-232.0%Net margin2
-27.4%Revenue growth, 20252
-$20.8MFree cash flow2
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue51¢$10.6M
- Research and development30¢$6.3M
- Other costs18¢$3.8M
Out of $20.7M in revenue.2 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenues | $20.7M | $28.5M | $33.9M |
| Costs of revenues | -$10.6M | -$17.4M | -$13.8M |
| Gross Profit | $10.1M | $11.1M | $20.1M |
| Research and development | -$6.3M | -$8.9M | -$9.9M |
| General and administrative | -$28.3M | -$23.6M | -$25.4M |
| Selling and marketing | -$18.3M | -$17.9M | -$16.4M |
| Other operating income | $2.0K | $6.4M | |
| Gain on disposal of long-lived assets | $479.0K | ||
| Foreign exchange gain (loss) | -$2.2M | -$192.0K | $200.0K |
| Impairment of intangible assets | -$696.0K | ||
| Total operating expenses | -$55.1M | -$50.8M | -$45.1M |
| Loss from operations | -$45.0M | -$39.6M | -$25.1M |
| Interest expense | -$840.0K | -$871.0K | -$15.0K |
| Interest income | $135.0K | $539.0K | $629.0K |
| Other income | $20.0K | $188.0K | $764.0K |
| Change in fair value of investments | -$179.0K | $1.7M | -$581.0K |
| Impairment loss of long-term investments | -$2.0M | ||
| Loss before income tax benefit and share of net loss in an equity investee | -$45.9M | -$38.1M | -$26.3M |
| Income tax benefit | $81.0K | ||
| Net loss before share of net loss in an equity investee | -$45.9M | -$38.1M | -$26.2M |
| Share of net loss in an equity investee | -$2.2M | -$1.2M | -$48.0K |
| Net loss | -$48.1M | -$39.3M | -$26.3M |
| Less:Loss attributable to redeemable noncontrolling interest | -$2.6M | ||
| Accretion to redeemable noncontrolling interest redemption value | $3.3M | ||
| Deemed dividends to Wuxi LP | $22.0K | ||
| Net loss attributable to CASI Pharmaceuticals, Inc. | -$48.1M | -$39.3M | -$27.0M |
| Net loss per share (basic) (in $ per share) | -$2.59 | -$2.56 | -$2.02 |
| Net loss per share (diluted) (in $ per share) | -$2.59 | -$2.56 | -$2.02 |
| Weighted average number of ordinary shares outstanding (basic) | 18.5M shares | 15.3M shares | 13.4M shares |
| Weighted average number of ordinary stock outstanding (diluted) | 18.5M shares | 15.3M shares | 13.4M shares |
| Foreign currency translation adjustment | -$11.0K | -$574.0K | -$1.1M |
| Total comprehensive loss | -$48.1M | -$39.8M | -$27.4M |
| Less: Comprehensive loss attributable to redeemable noncontrolling interest | -$3.2M | ||
| Comprehensive loss attributable to ordinary shareholders | -$48.1M | -$39.8M | -$24.2M |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $5.6M | $13.5M | |
| Investment in equity securities, at fair value | $2.6M | ||
| Accounts receivable, net of nil expected credit loss | $4.1M | $15.3M | |
| Inventories | $1.6M | $5.3M | |
| Prepaid expenses and other | $2.1M | $2.9M | |
| Total current assets | $13.5M | $39.6M | |
| Long-term investments | $1.7M | $1.9M | |
| Property, plant and equipment, net | $7.0M | $7.9M | |
| Intangible assets, net | $221.0K | $238.0K | |
| Right of use assets | $2.5M | $3.5M | |
| Other assets | $740.0K | $587.0K | |
| Total assets | $25.6M | $53.7M | |
| Accounts payable | $1.1M | $2.7M | |
| Bank borrowings | $1.0M | ||
| Accrued and other current liabilities | $24.2M | $15.3M | |
| Convertible notes due to a related party | $4.2M | ||
| Current portion of long term borrowing | $19.2M | $18.4M | |
| Total current liabilities | $49.7M | $36.5M | |
| Other liabilities | $13.3M | $15.4M | |
| Total liabilities | $62.9M | $51.8M | |
| $0.0001 par value, 500,000,000 shares authorized 20,967,869 shares and 15,904,533 shares issued at December 31, 2025 and 2024, respectively; 20,555,873 shares and 15,492,581 shares outstanding at December 31, 2025 and 2024, respectively | $2.0K | $2.0K | |
| Treasury shares, at cost: 411,996 shares and 411,952 shares held at December 31, 2025 and 2024 | -$9.6M | -$9.6M | |
| Additional paid-in capital | $722.2M | $713.3M | |
| Accumulated other comprehensive loss | -$1.8M | -$1.8M | |
| Accumulated deficit | -$748.1M | -$700.1M | |
| Total shareholders' (deficit) equity | -$37.3M | $1.9M | $24.2M |
| Total liabilities and shareholders' (deficit) equity | $25.6M | $53.7M | |
| Accounts receivable, expected credit loss | $0 | $0 | |
| Common Stock, Par Value (in dollars per share) | $0.00 | $0.00 | |
| Authorized common stock (in shares) | 500.0M shares | 500.0M shares | |
| Common Stock, Shares Issued (in shares) | 21.0M shares | 15.9M shares | |
| Common Stock, Shares Outstanding (in shares) | 20.6M shares | 15.5M shares | |
| Treasury stock, Shares Held (in shares) | 412.0K shares | 412.0K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$48.1M | -$39.3M | -$26.3M |
| Depreciation for property, plant and equipment | $1.2M | $1.3M | $2.5M |
| Amortization of intangible assets | $28.0K | $1.1M | $1.3M |
| Reduction in the carrying amount of the right-of-use assets | $1.0M | $1.1M | $988.0K |
| (Gain) loss on disposal of long-lived assets | $7.0K | -$479.0K | |
| Write-down of inventories | $1.1M | $4.8M | $0 |
| Impairment of intangible assets | $696.0K | ||
| Share-based compensation expense | $3.0M | $1.3M | $7.2M |
| Change in fair value of investments | $179.0K | -$1.7M | $581.0K |
| Share of net loss of an equity investee | $2.2M | $1.2M | $48.0K |
| Gain from extinguishment of investment in a convertible loan | -$474.0K | ||
| Impairment loss of long-term investments | $2.0M | ||
| Accounts receivable | $11.3M | -$5.8M | $3.4M |
| Receivable from a related party | $587.0K | -$587.0K | |
| Inventories | $2.5M | $5.8M | -$9.7M |
| Prepaid expenses and other | $9.0K | $319.0K | $701.0K |
| Accounts payable | -$1.7M | -$1.7M | $1.1M |
| Accrued liabilities and other liabilities | $6.4M | $1.5M | -$876.0K |
| Income tax payable | -$1.9M | ||
| Net cash used in operating activities | -$20.8M | -$29.2M | -$20.0M |
| Purchases of property, plant and equipment | -$16.0K | -$223.0K | -$204.0K |
| Proceeds from sale of intangible assets | $500.0K | ||
| Purchase of intangible assets | -$13.0K | -$17.0K | -$2.0M |
| Proceeds from sales of equity securities | $2.6M | $467.0K | |
| Cash paid to acquire equity interests in an equity method investee | -$1.6M | -$1.4M | |
| Purchase of short term investments and term deposits | -$1.4M | -$51.8M | |
| Proceeds from sales or maturity of short term investments and term deposits | $13.3M | $43.3M | |
| Proceeds from extinguishment of investment in a convertible loan | $1.0M | ||
| Net cash provided by (used in) investing activities | $951.0K | $11.2M | -$9.7M |
| Proceeds from issuance of ordinary shares | $5.9M | $15.0M | |
| Payment of issuance costs | -$681.0K | -$960.0K | |
| Proceeds from issuance of convertible note | $5.0M | ||
| Proceeds from exercise of share options | $56.0K | $2.1M | $109.0K |
| Dividend payment to Wuxi LP | -$718.0K | -$738.0K | |
| Proceeds from bank borrowings | $1.0M | ||
| Repurchase of ordinary shares | -$278.0K | ||
| Net cash provided by (used in) financing activities | $11.3M | $15.4M | -$907.0K |
| Effect of exchange rate change on cash and cash equivalents | $713.0K | -$1.1M | $518.0K |
| Net decrease in cash and cash equivalents | -$7.8M | -$3.6M | -$30.0M |
| Interest paid | $4.0K | ||
| Income taxes paid | $1.8M | ||
| Payables related to property, plant and equipment | $8.0K | $99.0K | |
| Exchange of redeemable noncontrolling interest to long term borrowing (Note 11) | $18.9M |
Former names
- CASI Pharmaceuticals Holdings, Inc.Jan 31, 2023 to Feb 14, 20233
Recent filings
- Sep 2, 20266-K
- Aug 14, 20266-K
- Aug 13, 20266-K
- Jul 15, 20266-K
- Jun 29, 20266-K
- Jun 23, 202625-NSE
- Jun 2, 20266-K
- May 18, 2026SCHEDULE 13D/A
- May 15, 202620-F
- Apr 28, 2026D
- Apr 23, 20263 OWNERSHIP DOCUMENT
- Apr 21, 2026NT 20-F
- Apr 20, 20266-K
- Apr 20, 20266-K
- Apr 20, 20263 OWNERSHIP DOCUMENT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6